These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32333596)

  • 21. Treatment of type I spinal muscular atrophy with noninvasive ventilation and gastrostomy feeding.
    Birnkrant DJ; Pope JF; Martin JE; Repucci AH; Eiben RM
    Pediatr Neurol; 1998 May; 18(5):407-10. PubMed ID: 9650680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
    Shin HJ; Na JH; Lee H; Lee YM
    Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies.
    Leon-Astudillo C; Brooks O; Salabarria SM; Coker M; Corti M; Lammers J; Plowman EK; Byrne BJ; Smith BK
    Pediatr Pulmonol; 2024 May; 59(5):1364-1371. PubMed ID: 38358081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module.
    Berti B; Fanelli L; de Sanctis R; Onesimo R; Palermo C; Leone D; Carnicella S; Norcia G; Forcina N; Coratti G; Giorgio V; Cerchiari A; Lucibello S; Finkel R; Pane M; Mercuri E
    J Neuromuscul Dis; 2021; 8(4):589-601. PubMed ID: 34024771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.
    Glanzman AM; Mazzone E; Main M; Pelliccioni M; Wood J; Swoboda KJ; Scott C; Pane M; Messina S; Bertini E; Mercuri E; Finkel RS
    Neuromuscul Disord; 2010 Mar; 20(3):155-61. PubMed ID: 20074952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment.
    McGrattan KE; Shell RD; Hurst-Davis R; Young SD; O'Brien E; Lavrov A; Wallach S; LaMarca N; Reyna SP; Darras BT
    J Neuromuscul Dis; 2023; 10(4):531-540. PubMed ID: 37092232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feeding difficulties in children and adolescents with spinal muscular atrophy type 2.
    Wadman RI; De Amicis R; Brusa C; Battezzati A; Bertoli S; Davis T; Main M; Manzur A; Mastella C; Munot P; Imbrigiotta N; Schottlaender L; Sarkozy A; Trucco F; Baranello G; Scoto M; Muntoni F
    Neuromuscul Disord; 2021 Feb; 31(2):101-112. PubMed ID: 33454188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
    Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
    Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spinal muscular atrophy: survival pattern and functional status.
    Chung BH; Wong VC; Ip P
    Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I.
    Finkel RS
    Neuromuscul Disord; 2013 Feb; 23(2):112-5. PubMed ID: 23146148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysphagia in spinal muscular atrophy type II: more than a bulbar problem?
    van den Engel-Hoek L; Erasmus CE; van Bruggen HW; de Swart BJ; Sie LT; Steenks MH; de Groot IJ
    Neurology; 2009 Nov; 73(21):1787-91. PubMed ID: 19933981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
    Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
    CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.
    Bianchi L; Sframeli M; Vantaggiato L; Vita GL; Ciranni A; Polito F; Oteri R; Gitto E; Di Giuseppe F; Angelucci S; Versaci A; Messina S; Vita G; Bini L; Aguennouz M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type 0 Spinal Muscular Atrophy: Further Delineation of Prenatal and Postnatal Features in 16 Patients.
    Grotto S; Cuisset JM; Marret S; Drunat S; Faure P; Audebert-Bellanger S; Desguerre I; Flurin V; Grebille AG; Guerrot AM; Journel H; Morin G; Plessis G; Renolleau S; Roume J; Simon-Bouy B; Touraine R; Willems M; Frébourg T; Verspyck E; Saugier-Veber P
    J Neuromuscul Dis; 2016 Nov; 3(4):487-495. PubMed ID: 27911332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feeding problems and malnutrition in spinal muscular atrophy type II.
    Messina S; Pane M; De Rose P; Vasta I; Sorleti D; Aloysius A; Sciarra F; Mangiola F; Kinali M; Bertini E; Mercuri E
    Neuromuscul Disord; 2008 May; 18(5):389-93. PubMed ID: 18420410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DySMA - an Instrument to Monitor Swallowing Function in Children with Spinal Muscular Atrophy ages 0 to 24 Months: Development, Consensus, and Pilot Testing.
    Zang J; Witt S; Johannsen J; Weiss D; Denecke J; Dumitrascu C; Nießen A; Quitmann JH; Pflug C; Flügel T
    J Neuromuscul Dis; 2024; 11(2):473-483. PubMed ID: 38457144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.